Hope beyond
the diagnosis
Advancing research. Connecting families. Honoring every child.
Our mission
Bringing hope to childhood cancer families through
research, community, and remembrance.
We exist so no family faces pediatric cancer or the loss of a child alone. Through research, trusted resources, and compassionate support, we bring hope today while investing in a better tomorrow.
Addie’s Research funds and advances Hepatoblastoma and rare pediatric liver cancer research with the goal of creating better, less toxic treatment options for children. Our work is rooted in one family’s experience with too few treatment options, and a commitment to help change that for the next child.
Research for tomorrow. Hope for today.
10 years of moving Hepatoblastoma
research forward.
$985K+
raised for Hepatoblastoma
research
18
countries connected globally
10
research and industry partners worldwide
6
published papers supported by funded research
Every dollar, partnership, and discovery moves us toward the same goal: better options for the next child.
Help us reach $1 million for Hepatoblastoma research.
How we help
Three ways we bring hope
Advance Research
Fund research focused on better, less toxic treatments for Hepatoblastoma and rare pediatric liver cancers.
Connect Families
Connect pediatric cancer families with trusted resources, education, and community, primarily through the Hepatoblastoma Resource Network.
Honor Every Child
Support pediatric cancer families through remembrance and carefully selected bereavement initiatives.
Why this work matters
As a researcher, you can see the potential in the science, but moving it forward takes partners who believe in the work too. Addie’s Research believed in ours, and their support has helped us keep pushing forward toward a clinical trial for Hepatoblastoma. I’m incredibly grateful for their partnership.
Dr. Michael Verneris, MD, Pediatric Hematology/Oncology, Children’s Hospital Colorado
Our research journey
Every step moves us closer.
What we funded, what researchers learned, and what happened next. A few of the milestones along the way, each with its own full story.
2026
Research is reaching patients, and families
CAR T-cell research is moving closer to patients, with an FDA-cleared clinical trial at Children’s Hospital Colorado preparing to include children with Hepatoblastoma. Our mission also expanded through a partnership with Momcology to support pediatric cancer families.
Children’s Hospital Colorado
Momcology2024
A new direction: CAR T-cell therapy
We partnered with Children’s Hospital Colorado to help fund pre-clinical CAR T-cell research for Hepatoblastoma, an entirely new approach to treating this disease, and celebrated progress toward clinical trials for volasertib.
Oncoheroes Biosciences2019
From the lab to published research
Research we helped support reached an important milestone with a scientific publication, while work continued toward a treatment option specifically for children with Hepatoblastoma. The Hepatoblastoma Resource Network also launched.
Hepatoblastoma Resource Network2017
Where it started
We walked into a research lab carrying questions born from Addie’s experience, and saw where her donated tumor tissue was being preserved for research. That year began our partnership with cc-TDI.
cc-TDIOur research and community partners
Vitalant Research Institute
Bordeaux Institute of Oncology
UCSF Benioff Children’s Hospitals
Eureka Therapeutics
Cincinnati Children’s
Addie’s story
It began with one little girl.
Addie’s story is the reason this work exists. The treatment options available to her were too few, and Addie’s Research exists to help create more options for the next child like Addie.
News & stories
The latest from Addie’s Research
- Hepatoblastoma Treatment, Relapse, and Research
A family-friendly guide to Hepatoblastoma treatment, relapse, side effects, and how research moves from lab work to Hepatoblastoma clinical trials.
Give Hope
Fund the next step.
Your gift advances Hepatoblastoma research and helps sustain trusted resources and compassionate support for pediatric cancer families.
Questions families ask
Understanding Hepatoblastoma
Answers here are educational, not medical advice. Please talk with your child’s care team about treatment decisions.
What is Hepatoblastoma?
Hepatoblastoma is the most common type of liver cancer in children, although it is still rare. It usually affects very young children, most often before age 3, and it is the most common form of liver cancer in newborns and infants. Diagnosis and treatment planning may include AFP blood testing, imaging, pathology, and staging to understand where the tumor is located and whether it can be safely removed.
Learn more in our Hepatoblastoma treatment and research guide, or from the Hepatoblastoma Resource Network and the National Cancer Institute.
How rare is Hepatoblastoma?
Hepatoblastoma is a rare childhood cancer even though it is the most common liver cancer in children. Because individual hospitals may see relatively few cases, families may benefit from care or consultation with teams experienced in pediatric liver tumors.
The Hepatoblastoma Resource Network can help families connect with experienced teams.
How is Hepatoblastoma treated?
Treatment usually combines chemotherapy with complete surgical removal of the tumor when possible. Some children receive chemotherapy before surgery, and liver transplant may be considered in selected cases when the tumor cannot be safely removed with conventional surgery. Treatment depends on the child’s risk group, extent of disease, and response to therapy.
Read more about treatment options in our Hepatoblastoma guide.
Why are new and less-toxic treatments needed?
Treatments such as cisplatin have helped cure many children with Hepatoblastoma, but they can also cause serious short- and long-term side effects. Research is needed both to create new options for high-risk, relapsed, or treatment-resistant disease and to reduce unnecessary toxicity for children who can be cured with less treatment.
Read why it matters in our Hepatoblastoma guide, and see how FAR-supported research is working toward better options in our Research Journey.
What happens when Hepatoblastoma relapses?
Relapse means the cancer has returned or progressed after treatment. There is no single approach that fits every child. Depending on prior therapy and where the disease is found, options may include additional chemotherapy, surgery, transplant in carefully selected situations, or a clinical trial. A second opinion from a pediatric liver tumor program may also be useful.
Learn more about relapse in our Hepatoblastoma guide, and find family resources through the Hepatoblastoma Resource Network.
How does preclinical research move toward a clinical trial?
Preclinical research tests an idea before it is studied in people. Researchers investigate tumor biology, potential targets, laboratory models, dosing, and safety. Promising work must then move through regulatory and trial-development steps before an experimental therapy can be tested in children.
See each step in our Hepatoblastoma guide, and an example in our 2024 CAR T-cell research milestone.
What Hepatoblastoma research has Addie’s Research helped fund?
Since 2017, FAR has helped support Hepatoblastoma research across multiple stages of development, from laboratory studies and drug testing to research partnerships working toward clinical translation. The Research Journey shows what FAR supported, what researchers learned, and what happened next.
Explore the full Research Journey.
How can families find Hepatoblastoma experts, treatment resources, and support?
The Hepatoblastoma Resource Network is a strong place to start for trusted information, family resources, community connection, and help navigating a rare diagnosis. Families can also ask their child’s oncology team whether consultation with a pediatric liver tumor program would be useful.
Visit the Hepatoblastoma Resource Network, or see selected pediatric liver tumor programs in our Hepatoblastoma guide.